Global Short Bowel Syndrome Market Overview
Short Bowel Syndrome Market was valued at US$ 850.5 million in 2024 and is projected to grow at a CAGR of 13.7% to reach US$ 3060.8 million by 2034.
Short bowel syndrome is related to poor motility, poor absorption of nutrients, and movement inside the intestine, generally occurs in people who have had at least half of their small intestine or partially short bowel syndrome is related to poor motility, poor absorption of nutrients, and movement inside the intestine, generally occurs in people who have had at least half of their small intestine or partially part of large intestine removed. It can be mild, moderate and severe in people, depending on small intestine functions. Moreover, people suffering from short bowel syndrome cannot absorb minerals, calories, protein, vitamins, fat, and enough water from food. Short bowel syndrome is caused due to factors such as intestinal diseases, intestinal injuries, and birth defects. At present, there is no cure for short bowel syndrome and the treatment is targeted towards symptoms. Therefore, the pharmaceutical industry is constantly involved in the research and developmental activity and in turn, it is expected to gain more share value during the forecast period.
For More Report Details, Download Free Sample PDF
Global Short Bowel Syndrome Market Drivers & Restraints
As per the Crohn’s& Colitis Foundation of America, approximately 10,000-20,000 people were suffered from short bowel syndrome in 2010. In addition to this, around 25% people reported with other complication within two years. Due to insufficient nutrients to the body, the rate of absorption decreased and many children suffered and died due to malnutrition. Increasing awareness due to the rapid improvements in healthcare and accessibility of epidemiological data to manage better short bowel disease in coming years. Besides, the state government in association with non-profit organizations offering grants and funds to manufacturers for the research and development of short bowel syndrome therapeutics. Hence, it is projected to attain significant market growth within the forecast period.
Global Short Bowel Syndrome Market Segmentations & Regional Insights
The short bowel syndrome market has been segmented on the basis of drug type, distribution channel, and region.
The drug type segment includes anti-diarrheals, proton pump inhibitors, histamine blockers, growth hormone, glucagon-like peptide, and others.
On the basis of the distribution channel, the global short bowel syndrome market has been segmented into specialty pharmacies, hospital pharmacies, and others.
Regional Insights:
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
Short Bowel Syndrome Market Regional Insights
On the basis of region, the global short bowel syndrome market has been segmented into North America, Latin America, Asia Pacific, Europe, Middle East and Africa. North America dominates the market due to large pool of people adopting drugs and requiring new treatment options. Asia-Pacific is expected to register faster growth over the forecast period due to major players in the market, huge R&D infrastructure and investment.
Report Scope:
Attribute |
Details |
Market Size 2024 |
US$ 850.5 million |
Projected Market Size 2034 |
US$ 3060.8 billion |
CAGR Growth Rate |
13.7.0% |
Base year for estimation |
2023 |
Forecast period |
2024 – 2034 |
Market representation |
Revenue in USD Billion & CAGR from 2024 to 2034 |
Market Segmentation |
By Drug Type - Anti-Diarrheals, Proton Pump Inhibitors, Histamine Blockers, Growth Hormone, Glucagon-like Peptide, and Others By Distribution Channel - Specialty Pharmacies, Hospital Pharmacies, and Others |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Short Bowel Syndrome Market report based on drug type, distribution channel, and region.
Short Bowel Syndrome Market, By Drug Type:
- Anti-Diarrheals
- Proton Pump Inhibitors
- Histamine Blockers
- Growth Hormone
- Glucagon-like Peptide
- Others
Short Bowel Syndrome Market, By Distribution Channel:
- Specialty Pharmacies
- Hospital Pharmacies
- Others
Short Bowel Syndrome Market, By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Global Short Bowel Syndrome Market Competitive Landscape & Key Players
The key players operating the Short Bowel Syndrome Market includes, Shire Plc, Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Swedish Orphan Biovitrum AB, Merck & Company, Inc., Pfizer Inc., Novartis AG, Mylan N.V., Johnson & Johnson and others.
Global Short Bowel Syndrome Market Recent News
Recent Development:
- In December 2023, Zealand Pharma A/S), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS) dependent on parenteral support.
- In October 2023, Ironwood Pharmaceuticals, Inc., a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week. This multicenter study of nine patients was designed to evaluate the safety, pharmacokinetics, and efficacy of apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog, on intestinal absorption in adult patients who have Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC). Positive interim results from this study were first announced in October 2022.
Global Short Bowel Syndrome Market Company Profile
- Teva Pharmaceutical Industries Ltd.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Shire Plc
- AstraZeneca Plc
- Swedish Orphan Biovitrum AB
- Merck & Company Inc.
- Pfizer Inc
- Novartis AG
- Mylan N.V.
- Johnson & Johnson
“*” marked represents similar segmentation in other categories in the respective section.
FAQs
Short Bowel Syndrome Market is segmented, By Drug Type (Anti-Diarrheals, Proton Pump Inhibitors, Histamine Blockers, Growth Hormone, Glucagon-like Peptide, and Others), By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, and Others)
Short Bowel Syndrome Market was valued at US$ 850.5 million in 2024 and is projected to grow at a CAGR of 13.7% to reach US$ 3060.8 million by 2034.
Rising prevalence of people suffering from short bowel syndrome is expected to drive the market.
Key players operating in the short bowel syndrome market includesShire Plc, Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Swedish Orphan Biovitrum AB, Merck & Company, Inc., Pfizer Inc., Novartis AG, Mylan N.V., Johnson & Johnson and others.